Detalhe da pesquisa
1.
CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity.
Immunity
; 54(5): 1066-1082.e5, 2021 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33951417
2.
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.
Proc Natl Acad Sci U S A
; 118(19)2021 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33893175
3.
A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation.
Clin Infect Dis
; 73(11): e4269-e4277, 2021 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33175132
4.
Persistence of SARS-CoV-2-Specific IgG in Children 6 Months After Infection, Australia.
Emerg Infect Dis
; 27(8): 2233-2235, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34016252
5.
Ancestral, Delta, and Omicron (BA.1) SARS-CoV-2 strains are dependent on serine proteases for entry throughout the human respiratory tract.
Med
; 4(12): 944-955.e7, 2023 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37769654
6.
Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post-vaccination but persist for at least 6 months.
Influenza Other Respir Viruses
; 17(1): e13072, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36451293
7.
Macrophage ACE2 is necessary for SARS-CoV-2 replication and subsequent cytokine responses that restrict continued virion release.
Sci Signal
; 16(782): eabq1366, 2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37098119
8.
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial.
EBioMedicine
; 97: 104842, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37865043
9.
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.
EBioMedicine
; 92: 104574, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37148585
10.
Robust SARS-CoV-2 T cell responses with common TCRαß motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells.
Cell Rep Med
; 4(4): 101017, 2023 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37030296
11.
Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster.
EBioMedicine
; 98: 104878, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38016322
12.
Long-Read RNA Sequencing Identifies Polyadenylation Elongation and Differential Transcript Usage of Host Transcripts During SARS-CoV-2 In Vitro Infection.
Front Immunol
; 13: 832223, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35464437
13.
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2.
Front Immunol
; 13: 889372, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35967361
14.
Comparison of Seroconversion in Children and Adults With Mild COVID-19.
JAMA Netw Open
; 5(3): e221313, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35262717
15.
Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2.
Front Immunol
; 13: 1122516, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36703991
16.
Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques.
Nat Commun
; 12(1): 1403, 2021 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33658497
17.
Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay.
JCI Insight
; 6(16)2021 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34251356
18.
Transcriptional and epi-transcriptional dynamics of SARS-CoV-2 during cellular infection.
Cell Rep
; 35(6): 109108, 2021 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33961822
19.
A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2.
EBioMedicine
; 74: 103729, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34871960
20.
Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19.
Nat Commun
; 12(1): 1162, 2021 02 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33608522